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Background: Valacyclovir has been used for prophylaxis against cytomegalovirus (CMV) infection after
hematopoietic stem cell transplantation (HSCT). We investigated the efficacy and safety of high-dose Valacyclovir as
pre-emptive therapy in patients with CMV antigenemia after HSCT.
Methods: In a retrospective single center study of 61 patients, we compared the rates of viral clearance, recurrent
antigenemia and adverse events in patients with pp65 CMV antigenemia who received high dose Valacyclovir
(n = 15), Valganciclovir (n = 16), and Foscarnet (n = 30).
Results: Overall, 60/61 (98 %) of cases achieved CMV antigenemia clearance by day 28, and no patient developed
CMV disease. After adjusting for age, sex, diagnosis, CMV serological status, donor type, CMV antigen level,
graft-versus-host disease (GVHD) therapy, and conditioning regimen, there were no significant differences in the
rates of viral clearance at day 14 in patients who received Valganciclovir (0.18, 95 % confidence interval (CI) 0.01 to
2.15, p = 0.17) and Foscarnet (OR 0.22, 95 % CI 0.03 to 2.40, p = 0.22), compared with Valacyclovir (assigned
OR = 1.00). Recurrent antigenemia by day 180 after clearance of the initial CMV episode occurred in 34/61 (56 %) of
patients. Using the multivariate model adjusting for the same covariates, there were also no significant differences
in secondary episodes of CMV between treatment groups. With regards to adverse effect monitoring, Foscarnet led
to significantly increased creatinine levels (P = 0.009), while Valganciclovir led to significant decrease in neutrophil
counts (P = 0.012).
Conclusion: High dose Valacyclovir is a potential alternative to Valganciclovir and Foscarnet in the stable post-HSCT
patient who has cytopenia and is not keen for inpatient treatment of CMV antigenemia.Background
Cytomegalovirus (CMV) infection poses a serious clin-
ical challenge to hematopoietic stem cell transplant
(HSCT) patients as it can result in numerous complica-
tions associated with significant morbidity and mortality.
These include retinitis, encephalitis, pneumonia, hepa-
titis and gastrointestinal ulceration. Two approaches for
the prevention of CMV infection are currently practiced.
The first is universal prophylaxis with routine adminis-
tration of an antiviral agent to all patients after trans-
plant. Benefits of prophylaxis is that monitoring may not* Correspondence: shinyeu.ong@mohh.com.sg
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tients are exposed to drug-related toxicities unnecessar-
ily. The second approach is pre-emptive therapy, that is
initiated when CMV infection is detected, but before the
development of CMV-associated symptoms. Pre-emptive
therapy depends on early detection of CMV in blood,
which is aided by the ready availability of pp65 antigene-
mia and DNA PCR-based assays. Both approaches are
equally effective in preventing CMV disease.
Ganciclovir, and its modified oral formulation, Valgan-
ciclovir (GCV), are first line agents for pre-emptive therapy
against CMV [1–3]. When cytopenias are present, Foscar-
net is used as an alternative. Although as effective as ganci-
clovir, Foscarnet is associated with renal toxicity and
requires inpatient therapy, hence it is reserved as secondle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
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an ideal pre-emptive therapeutic agent due to its low tox-
icity profile, and excellent bioavailability after oral adminis-
tration [6]. High dose Valacyclovir has already been shown
to be safe and effective in CMV prophylaxis after solid
organ and stem cell transplantation [7–13], but has not
been adequately studied as an antiviral for pre-emptive
therapy against CMV antigenemia. Valacyclovir is poten-
tially an important alternative agent in patients with cytope-
nia who are not eligible for Ganciclovir, and who are
unwilling to be hospitalized for intravenous Foscarnet.
We hypothesized that Valacyclovir could be useful as a
single agent against CMV antigenemia after HSCT, with-
out significant hematologic or renal toxicity. To evaluate
this treatment approach, a retrospective cohort study
comparing the use of Valacyclovir, Valganciclovir, and
Foscarnet was performed in our institution. The primary
outcome was viremia clearance. Secondary outcomes in-
cluded recurrent antigenemia and adverse events.
Methods
Patients
All consecutive adult patients who underwent allogeneic
bone marrow, peripheral blood stem cell, or cord blood
transplantation at Singapore General Hospital between
January 2008 and September 2011 were included if they
had an initial episode of CMV antigenemia before a sin-
gle antiviral (Valacyclovir, Valganciclovir, or Foscarnet)
was started for pre-emptive therapy. Departmental prac-
tice guidelines, integrated with patients’ preferences, de-
termined the choice of antiviral regimen. Ganciclovir is
the first line pre-emptive therapy for CMV in our inpa-
tients, while Foscarnet is used in patients with neutropenia
or previous ganciclovir treatment failure. Outpatients with
normal gastrointestinal absorption received Valganciclovir,
while patients with neutropenia received Valacyclovir. Pa-
tients who developed CMV disease before or at the time of
the initial detection of CMV antigenemia were excluded.
All patients also received acyclovir for prophylaxis against
varicella zoster virus and trimethoprim-sulfamethoxazole
for Pneumocystis jirovecii prophylaxis until immuno-
suppression was discontinued. Prophylaxis for fungal
infections was either posaconazole or itraconazole.
Calcineurin-inhibitor-based therapies were the most com-
monly used GVHD prophylaxis regimens, with the inclu-
sion of anti-thymocyte globulins (ATG) in unrelated donor
transplants. All participants gave their informed consent
for participation in the research database and the database
collection was approved by the institutional review board
of the Singapore General Hospital.
Detection of CMV reactivation
All patients were screened for CMV infection using a
CMV pp65 antigenemia assay at least twice in the firstweek after transplant, and at least once a week subse-
quently. The CMV antigenemia assay was performed as
described previously [14], and ≥ 1 CMV antigen positive
cell per million leukocytes was used as the threshold for
pre-emptive therapy.
Pre-emptive therapy
Patients were treated with either Foscarnet at 90 mg/kg
twice daily (BID), or 45 mg/kg BID if creatinine clear-
ance is less than 60 ml/min; Valganciclovir a 900 mg
BID or 450 mg BID if creatinine clearance is less than
60 ml/min, or Valacyclovir 2 g four times daily (QID) or
1 g QID in the presence of renal impairment. The me-
dian duration of treatment was 14 days. Clearance of
CMV antigenemia was defined as 0 positive cells per
million leukocytes via the CMV pp65 antigenemia assay.
The incidence of recurrent CMV antigenemia after
treatment with each agent was recorded for 180 days
after the clearance of an initial episode of CMV antige-
nemia. Patients who relapsed after successful clearance
of CMV antigenemia were treated at the discretion of
the physician.
Monitoring of adverse events
Patients were monitored for the development of CMV
disease as defined previously [15], as well as significant
side effects of Valacyclovir, Valganciclovir, or Foscarnet.
Haemograms and biochemical panels were performed at
least once a week to look for neutropenia, thrombocytopenia
and renal impairment. Mortality rates and causes of mortality
for up to 6 months post-transplant were recorded.
Statistical analysis
Values are expressed as median (range), and the signifi-
cance of differences was determined using the chi-
square test or analysis of variance, as appropriate. Some
analyses compared changes in pre- and post-treatment
cell counts and serum creatinine between two groups;
these were analyzed using the paired t-test. Multivariable
logistic regression models were used to determine the
odds of viral clearance at day 14, and of recurrent anti-
genemia in patients treated with Valganciclovir and Fos-
carnet, compared with Valacyclovir. Potential confounders
considered include age, gender, CMV serological status,
donor type, CMV antigen level at diagnosis, conditioning
regimen, and graft-versus-host disease therapy.
Results
Patient characteristics
The demographic characteristics of the three groups of
patients are shown in Table 1. Comparisons of the three
groups for parameters that could influence CMV reactiva-
tion showed significant difference with respect to age, but
not CMV serological status, sex, donor type, indication for
Table 1 Patient characteristics
All (n = 61) Valacyclovir (n = 15) Valganciclovir (n = 16) Foscarnet (n = 30) Pa
Median age, years (range) 41 (16–66) 47 (18–61) 50 (30–57) 37 (16–66) 0.017
Male, N (%) 31 (50.8) 9 (60.0) 5 (31.3) 27 (56.7) 0.186
Diagnosis, N (%) 0.509
Acute myeloid leukemia 30 (49.2) 7 (46.7) 9 (56.3) 14 (46.7)
Acute lymphoid leukemia 13 (21.3) 3 (20.0) 1 (6.3) 9 (30.0)
Non-Hodgkin’s lymphoma 2 (3.3) 1 (6.7) 1 (6.3) 0 (0.0)
Myelodysplastic syndrome 6 (9.8) 1 (6.7) 1 (6.3) 4 (13.3)
Others 10 (16.4) 3 (20.0) 4 (25.0) 3 (10.0)
Conditioning regimen, N (%) 0.374
Myeloabalative 32 (53.3) 9 (60.0) 11 (68.8) 12 (41.4)
Non-Myeloabalative 14 (23.3) 2 (13.3) 3 (18.8) 9 (31.0)
Reduced Intensity 14 (23.3) 4 (26.7) 2 (12.5) 8 (27.6)
Donor type, N (%) 0.078
Related 31 (50.8) 11 (73.3) 10 (62.5) 10 (33.3)
Unrelated 21 (34.4) 2 (13.3) 5 (31.3) 14 (46.7)
Cord Blood 9 (14.8) 2 (13.3) 1 (6.25) 6 (20.0)
CMV serologic status, N (%) 0.586
Donor-/recipient+ 9 (14.8) 1 (6.7) 3 (18.8) 5 (16.7)
Donor+/recipient+ 52 (85.3) 14 (93.3) 13 (81.3) 25 (83.3)
GVHD (during study) 0.155
None 27 (44.3) 5 (33.3) 4 (25.0) 18 (60.0)
Grade I-II 30 (49.2) 9 (60.0) 10 (62.5) 11 (36.7)
Grade II-IV 4 (6.6) 1 (6.7) 2 (12.5) 1 (33.3)
GVHD treatment 0.119
None 25 (41.0) 5 (33.3) 3 (18.8) 17 (56.7)
Steroids 30 (49.1) 9 (60.0) 11 (68.9) 10 (33.3)
Others 6 (9.8) 1 (6.7) 2 (12.5) 3 (10.0)
Pre-treatment laboratory results, median (range)
Creatinine (μM) 78 (40–240) 86 (46–182) 72 (44–240) 78 (40–205) 0.601
ANC (x103/mm3) 2.6 (0.2-22.8) 2.4 (0.2-6.6) 3.6 (1.1-15.6) 1.7 (0.8-22.8) 0.093
Platelet (x103/mm3) 64 (7–260) 98 (15–197) 68 (7–244) 32.5 (8–260) 0.053
CMV, cytomegalovirus; GVHD, graft versus host disease; ANC, absolute neutrophil count
aP value for difference by treatment group, based on chi-square test or analysis of variance
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systemic corticosteroids or other agents (e.g. ertanercept,
mycophenolate mofetil, tacrolimus) for treatment of GVHD
were statistically similar between groups.
CMV antigenemia and pre-emptive treatment
The median number of CMV antigen-positive cells at
the initiation of pre-emptive therapy did not differ be-
tween groups (P = 0.77), and the median viral load for all
included patients was 3 (range 1 to 750). Overall, 60/61
(98 %) of cases achieved CMV antigenemia clearance by
day 28, with no significant differences between treatment
groups (p = 0.591). By day 14, clearance rates amonggroups who received Valacyclovir, Valganciclovir, and
Foscarnet were 14/15 (93 %), 13/16 (81 %), and 22/30
(73 %) respectively. After adjusting for age, sex, diagno-
sis, CMV serological status, donor type, CMV antigen
level, GVHD therapy, and conditioning regimen, there
were no significant differences in the rates of viral clear-
ance at day 14 in patients who received Valganciclovir
(odds ratio (OR) 0.18, 95 % confidence interval (CI) 0.01
to 2.15, p = 0.17) and Foscarnet (OR 0.22, 95 % CI 0.03
to 2.40, p = 0.22), compared with Valacyclovir (assigned
OR = 1.00).
Although high rates of CMV clearance were achieved,
recurrent antigenemia by day 180 after clearance of the
Table 2 Response to pre-emptive CMV therapy
All (n = 61) Valacyclovir (n = 15) Valganciclovir (n = 16) Foscarnet (n = 30) P
Median time to antigenemia (days from transplant, range) 27 (12–387) 39 (16–387) 31.5 (15–119) 24.5 (12–104) 0.084
Median viral load (No. of CMV positive cells
per million leukocytes, range)
3 (1–750) 3 (1–40) 3 (2–181) 3.5 (1–750) 0.772
Clearance, N (%) 60 (98.1) 15 (100) 16 (100) 29 (96.7) 0.591
Recurrent antigenemia, N (%) 34 (55.8) 7 (46.7) 11 (68.8) 16 (53.3) 0.434
Median days to recurrence 43.5 (11–173) 59 (27–173) 42 (14–94) 38 (11–163) 0.081
CMV, cytomegalovirus
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adjusting for the same covariates, there were no signifi-
cant differences in secondary episodes of CMV among
patients who received Valganciclovir (OR 3.36, 95 % CI
0.62 to 18.3, p = 0.17) and Foscarnet (OR 1.02, 95 % CI
0.20 to 5.25, p = 0.98, compared with Valacyclovir (OR =
1.00). No patients developed CMV disease during the
course of the study. Response to pre-emptive CMV
treatment using the three different anti-virals are de-
tailed in Table 2.
Adverse events and survival
The elevation in serum creatinine levels was significantly
higher after treatment with Foscarnet, compared to Vala-
cyclovir or Valganciclovir (P = 0.009). Treatment with Val-
ganciclovir led to a significant decrease in neutrophil
counts, compared to Foscarnet or Valacyclovir (P = 0.012).
Changes in pre- and post-treatment platelet levels did not
differ significantly between groups (Table 3). One patient
died of neutropenic enterocolitis on post-transplant day
102 in the Valacyclovir group, one patient died of disease
progression on post-transplant day 138 in the Valganciclo-
vir group, and three patients died of disease progression
and sepsis on post-transplant days 81, 129, and 131 in the
Foscarnet group.
Discussion
In this retrospective study, pre-emptive therapy with
Valacyclovir, Valganciclovir and Foscarnet achieved high
viral clearance rates in post-HSCT patients with CMV
antigenemia (98 %). After adjusting for potential con-
founders including age, sex, CMV serotype, CMV anti-
gen level at diagnosis, donor type, conditioning regimen
and GVHD treatment, the rates of viral clearance andTable 3 Hematological and renal toxicity of treatment
All (n = 61) Valacyclovir (n
Change in parameter (post-treatment – pre-treatment), median (range)
Creatinine (μM) 14 (−31 to 126) 2 (−31 to 57)
ANC (x103/mm3) −0.05 (−20.6 to 5.0) 0.19 (−4.2 to 3
Platelet (x103/mm3) 6 (−123 to 196) 6 (−72 to 82)
ANC, Absolute neutrophil countrecurrent antigenemia were not significantly different in
patients receiving high dose Valacyclovir, compared with
Ganciclovir or Foscarnet. Viral clearance with Valacyclo-
vir was achieved with significantly less reduction in neu-
trophil count or rise in creatinine levels. However, it is
important to bear in mind that patients who received
Valacyclovir in our study were discharged outpatients
who were at least one month post-transplant, had no
other active infection, and were not debilitated. Thus
our findings may only extend to the stable post-HSCT
patient.
Another limitation of our study is the use of a low
threshold value of 1 CMV-positive cell per million leu-
kocytes to start pre-emptive therapy. It has been sug-
gested that low positive results may represent transient
reactivation [16], or even a rare false positive result [17],
hence clearance may in part be spontaneous. However,
Boeckh et al. showed that the discontinuation of gancy-
clovir below the threshold of 3 positive cells per 50,000
leukocytes led to a risk of CMV disease [18]. When a
single positive cell is used as trigger, the rate of CMV
disease was reduced [19]. Other investigators have also
used a single positive cell as trigger, recognizing that
even low viral loads might be significant in the HSCT
patient [16, 20, 21]. Given the rapid doubling time of
CMV in immunosuppressed paients [22], withholding
anti-CMV therapy may pose significant risks. Future
studies applying a higher threshold to begin pre-emptive
therapyin a larger group of patients are needed to con-
firm the therapeutic effect of Valacyclovir in high-level
CMV antigenemia.
To our knowledge, no previous report has investigated
the use of Valacyclovir for pre-emptive therapy of CMV
antigenemia, although several randomized and= 15) Valganciclovir (n = 16) Foscarnet (n = 30) P
−2.5 (−70 to 73) 31.6 (−65 to 126) 0.009
) −1.5 (−7.5 to −1.1) 1.1 (−20.6 to 5.0) 0.012
−7.5 (−123 to 196) 13 (−92 to 150) 0.335
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Valacyclovir as prophylactic therapy. For example, re-
sults from large randomized multicenter studies have
shown that Valacyclovir is more effective in preventing
CMV antigenemia than oral acyclovir [11], and has simi-
lar efficacy as Ganciclovir in preventing CMV infection
and disease [12]. Similarly, retrospective reports have
established the potential benefit of Valacyclovir as a
prophylactic agent against CMV reactivation, compared
with no or other forms of CMV prophylaxis, with sig-
nificantly reduced rates and delay of CMV reactivation
[10, 13]. The small sample size in our study precludes
definitive conclusions about the efficacy of Valacyclovir
as pre-emptive therapy in HSCT patients, but results are
encouraging. Importantly, Valacyclovir represents a cost
effective alternative to Valganciclovir [23].
Limitations of this study include its retrospective study
design, non-randomized treatment allocation, and small
sample size. In recent years, more institutions have
switched from pp65 antigenemia assays to quantitative
PCR methods to guide pre-emptive therapy. PCR based
methods are rapid, more sensitive, provide more precise
quantitation of CMV, and can be used in patients with
severe neutropenia. Its disadvantage includes inter-assay
and inter-laboratory variability in viral load reporting,
which has complicated attempts to standardize thresh-
olds for initiating and stopping pre-emtive therapy. Re-
cently, the WHO international reference standard was
developed, which enables uniform viral load reporting
and interpretation. It remains to be studied if the viral
load threshold for preemptive therapy using Valacyclovir
is comparable to that using Valganciclovir or Foscarnet.Conclusions
In conclusion, pre-emptive Valacyclovir, Foscarnet and
Valacyclovir led to similar clearance of CMV antigene-
mia and rates of recurrence. High dose Valacyclovir is
potentially a safe and cost-effective option for pre-
emptive treatment of CMV antigenemia in the stable
post-HSCT patient who has cytopenia or prefers out-
patient treatment. These findings must be interpreted in
light of limitations inherent to retrospective observa-
tional studies. Further prospective randomized studies
are needed to validate the efficacy suggested by the re-
sults of this retrospective study.
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